

# LIST OF PRODUCTS



	PRODUCT	TERRITORY	REFERENCE PRODUCTS	STRENGTHS AND DOSAGES	THERAPEUTIC USE
Marketed Product	FENTANYL TDS	Europe	Durogesic® (Janssen)	25, 50, 75, 100 mcg/h	Management of pain in opioid-tolerant patients
	RIVASTIGMINE TDS *	Latin America	Exelon® (Novartis)	4.6; 9.5 and 13.3 mg/24 h	Alzheimer disease. Dementia associated with Parkinson disease
	ESTRADIOL GEL	Argentina	Estrogel® (Ascend)	0.06%	Hormonal replacement therapy
	TESTOSTERONE GEL	Argentina	Androgel® (Abbvie)	1%	Replacement therapy for deficiency or absence of endogenous testosterone
	DICLOFENAC SODIUM GEL 1%	USA	Voltaren® (GSK)	1%	Osteoarthritis, soft-tissue rheumatism, traumatism
	DICLOFENAC SODIUM GEL 5%	Argentina	Diclac® (Hexal)	5%	Osteoarthritis, soft-tissue rheumatism, traumatism
In BE Stage	BUPRENORPHINE TDS *	Brazil	Butrans® (Purdue Pharma)	5; 7.5; 10; 15 and 20 mcg/h	Moderate to severe chronic pain
Developed Formulation	SELEGILINE TDS *	Europe (compassionate use)	Emsam® (Dey L.P./Somerset)	6; 9 and 12 mg/d	Major depressive disorders
	METHYLPHENIDATE TDS *		Daytrana® (Noven)	10; 15; 20 and 30 mg/9 hours	Attention Deficit Hyperactivity Disorder (ADHD)
	TESTOSTERONE GEL		Androgel® (Abbvie)	1.62%	Replacement therapy for deficiency or absence of endogenous testosterone
Pharmaceutical Development Stage	ROTIGOTINE TDS		Neupro® (UCB)	1; 2; 3; 4; 6 y 8 mg/24h	Parkinson disease
	LIDOCAINE TDS		Lidoderm® (Endo) Versatis® (Grünenthal)	5%	Pain relief associated with post-herpetic neuralgia
	RIVASTIGMINE MULTIDAYS TDS		Rivalif® (Luye)	4.6 y 9.5 mg/24 horas	Alzheimer disease. Dementia associated with Parkinson disease
	IBUPROFENO TDS		Neurofen® (Reckitt Benckiser)	200 mg	short-term symptomatic treatment of local pain in acute muscular strain

\* Lower drug content and smaller patch size than the Reference Product.

[RETURN TO WEBSITE](#)